Health & Biotech
ScoPo’s Powerplays: Could ASX health stocks up for third week be a start of a Christmas rally?
Health & Biotech
ASX Health Stocks: Singular jumps 18pc after securing funds, Tax Office wipes smile off Pacific
Health & Biotech
Why these ASX firms are shying away from the pot stock label – Part Two
Health & Biotech
US FDA grants Argenica Orphan Drug designation to treat ‘devastating condition’ in newborns
Health & Biotech
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Health & Biotech
Melodiol subsidiary HHI Australia delivers $1 million revenue in October
Health & Biotech
ASX Health Stocks: EBR stumbles 11pc after warning of FDA delay; Firebrick’s trial data shows ‘inaccuracies’
Health & Biotech
Why these ASX firms are shying away from the ‘pot stock’ label – Part One
Health & Biotech
ASX Health Stocks: Forget surgery, Orthocell says tennis elbow can be fixed with its tendon cell therapy
Health & Biotech
ASX Health Stocks: 4DX skyrockets 54pc after US update on its XV LVAS scanning device
Health & Biotech
Argenica gets cash boost ahead of critical Phase 2 clinical trial
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Yoga = chill. Fact. And ASX health stocks up for second week
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.